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Phosphodiesterase-5 inhibition 
preserves renal hemodynamics 
and function in mice with diabetic 
kidney disease by modulating miR-
22 and BMP7
Riccardo Pofi1,*, Daniela Fiore1,*, Rita De Gaetano2, Giuseppe Panio2, Daniele Gianfrilli1, 
Carlotta Pozza1, Federica Barbagallo1, Yang Kevin Xiang3, Konstantinos Giannakakis4, 
Susanna Morano1, Andrea Lenzi1, Fabio Naro2, Andrea M. Isidori1,† & Mary Anna Venneri1,†
Diabetic Nephropathy (DN) is the leading cause of end-stage renal disease. Preclinical and experimental 
studies show that PDE5 inhibitors (PDE5is) exert protective effects in DN improving perivascular 
inflammation. Using a mouse model of diabetic kidney injury we investigated the protective proprieties 
of PDE5is on renal hemodynamics and the molecular mechanisms involved. PDE5i treatment 
prevented the development of DN-related hypertension (P < 0.001), the increase of urine albumin 
creatinine ratio (P < 0.01), the fall in glomerular filtration rate (P < 0.001), and improved renal resistive 
index (P < 0.001) and kidney microcirculation. Moreover PDE5i attenuated the rise of nephropathy 
biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and neutrophil gelatinase-
associated lipocalin, NGAL. In treated animals, blood vessel perfusion was improved and vascular 
leakage reduced, suggesting preserved renal endothelium integrity, as confirmed by higher capillary 
density, number of CD31+ cells and pericyte coverage. Analysis of the mechanisms involved revealed 
the induction of bone morphogenetic protein-7 (BMP7) expression, a critical regulator of angiogenesis 
and kidney homeostasis, through a PDE5i-dependent downregulation of miR-22. In conclusion PDE5i 
slows the progression of DN in mice, improving hemodynamic parameters and vessel integrity. 
Regulation of miR-22/BMP7, an unknown mechanism of PDE5is in nephrovascular protection, might 
represent a novel therapeutic option for treatment of diabetic complications.
The vascular complications of diabetes dramatically increase the disease’s morbidity and mortality of patients. One 
third of diabetes patients suffers from diabetic nephropathy (DN)1, a leading cause of end-stage renal disease2,3. 
To date, effective treatment in halting or reversing the natural progression of DN remains uncertain4–8.
As with most diabetes-associated co-morbidities, the pathophysiology is multifactorial and the molecular 
pathways involved are complex. Glomerular endothelial cell (EC) injury plays a major role in the development and 
progression of diabetic kidney disease, that is considered the result of converging hemodynamic and metabolic 
insults9. In kidney, phosphodiesterase type 5 (PDE5), the cyclic guanosine monophosphate (cGMP) hydrolyzing 
enzyme, is expressed in the glomeruli, mesangial cells, cortical tubules, inner medullary collecting duct and plays 
a critical role in the regulation of excretory function10. In diabetes, glomerular cGMP production is decreased, 
PDE5 activity is increased11 and changes in the cGMP-NO pathway leads to a rise in intra-glomerular pressure12. 
PDE5 inhibitors (PDE5is) may have an active role in the management of DN13 by reducing glomerulosclerosis 
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and proteinuria and improving vascular inflammation and podocyte count in experimental diabetes models14–17. 
These findings, together with the modulation of inflammatory14,18 and angiogenic mediators, and endothelial 
function19,20 in murine and human models, support the use of PDE5i to prevent complications of the diabetic 
kidney.
Intriguingly, sildenafil, a potent PDE5i, was also associated with improved kidney function in patients with 
pulmonary arterial hypertension21 and in type-2 diabetes (T2DM) patients22. However, little information is avail-
able on the effect of PDE5is on the progression of nephrovascular impairment in DN. Furthermore, the molecular 
factors involved in nephroprotection have not yet been characterized.
The renal resistive index (RRI), measured in the interlobar arteries of both kidneys by renal color Doppler 
ultrasound (RDU), offers a measure of intraparenchymal renal resistances, which have been correlated with DN 
progression in humans23–25.
The aim of this study is to identify the targets of PDE5is in DN and the mechanisms involved in renal pro-
tection, monitoring in vivo kidney flow parameters by RDU and analyzing histological, perfusion, cellular and 
molecular modulation.
Materials and Methods
Animal model. 12-week-old male CD1 mice were randomly assigned to one of four groups (8 mice in each 
group): vehicle (CTRL), sildenafil (SILD), streptozotocin (STZ) or streptozotocin + sildenafil (STZ + SILD). 
Diabetes was induced using a single intraperitoneal injection (IP) of streptozotocin (STZ: 150 mg/kg, Sigma 
Aldrich). We used high-dose STZ protocol to induce insulin-dependent diabetes mellitus in mice because of its 
toxic effects on islet beta cells18. To reduce STZ acute renal toxicity we pre-treated mice with the SGLT-2 inhibi-
tor phlorizin, as previously shown26. After 3 days of STZ-diabetic induction, sildenafil citrate (1.6 mg/kg, SILD: 
Viagra, Pfizer in saline 0.3% aqueous solution of DMSO) was administered IP daily, for 4 weeks. Appropriate 
vehicle controls were performed for each treatment (STZ and/or sildenafil). All STZ-induced animals were sup-
plied with 10% sucrose water for 72 h after STZ to counteract post-injection hypoglycemia. Body weight and food 
consumption were monitored every 2 weeks in all animals (data not shown). For the time course flow cytometry 
study, 12-week-old male CD1 mice were randomly assigned (4 mice to each of CTRL, SILD, STZ, STZ + SILD) 
and analyzed at 3 time points. All mice were kept in a pathogen-free facility. All experiments were performed in 
accordance with Italian law (Law Decree 2010/63EU) and the study was approved by the Sapienza University’s 
Animal Research Ethics Committee and by the Italian Ministry of Health (165/2016-PR). Housing of one mouse 
per cage allowed individual measurement of food and water intake and urine output. A drop of tail blood after 
3 h fasting was used to monitor glucose concentrations by MediSense Precision Plus kit (Abbott Diagnostics, 
Melbourne, Victoria, Australia). Criteria for euthanasia were based on an independent assessment by a veterinar-
ian according to AAALAC guidelines.
Clinical and laboratory investigation. The tail artery cuff method was used to measure MAP and heart 
rate (HR). Baseline and after sildenafil treatment blood glucose, triglycerides, creatinine, glycosuria, albuminuria, 
creatininuria were assessed by Siemens Advia 1800 analyzer. SuPAR/CD87 levels were measured by ELISA kit 
(Cohesion Biosciences).
Renal artery Color Doppler Ultrasound. Renal Doppler ultrasound was performed using a Philips 
IU22™ ultrasound system equipped with a Broadband Linear Array Transducer 17 MHz extended frequency 
range. Renal Doppler blood flow was obtained taking the mean value of 3 different evaluations: peripheral arter-
ies, mesorenal arteries and renal artery origin over both kidneys, guided by color flow mapping. These evaluations 
were performed at baseline and during treatment. A single investigator blinded to the treatment performed the 
Doppler ultrasound examination. Doppler flow was measured using an anterior approach. The measured param-
eters were: kidney length and volume, peak-systolic velocity (PSV), end-diastolic velocity (EDV), mean diastolic 
velocity (MDV) renal resistive index (RRI), acceleration time (AT) and HR. RRI was calculated as (PSV-EDV)/
PSV. PSV and EDV are expressed as cm/s. Kidney volume was calculated with the Ellipsoid formula.
In vivo endothelial permeability measurements. EC permeability in renal tissue was estimated using 
vascular tracers of different molecular weights, FITC dextrans and Evan’s Blue (Sigma Aldrich). Mice were 
injected through the tail vein with 0.2 ml of 0.9% saline solution containing 200 mg/ml of 40 kDa dextran or 1% 
of Evan’s Blue (0.96 kDa). The animals were euthanatized thirty (dextran) or sixty (Evan’s blue) minutes after 
injection of the dyes. Evan’s Blue extravasation was quantified by incubating 100 mg of renal tissue for 24 h at 
55 °C with 500 μ L formamide to extract the extravasated dye; optical density was then measured at 610 nm and 
converted into ng of dye per mg of tissue. The experiment was repeated in triplicate.
Tissues from FITC dextrans-injected mice were processed for immunofluorescence analysis. Kidneys 
were obtained from surgical resections, embedded in OCT (Tissue-Tek, Torrance, CA) compound and 
snap-frozen. Sections were cut into 20-μ m thickness by cryostat (Leica Microsystems, Germany). Extravasation of 
FITC–dextran produced a fluorescence outside the vessels that was classified as weak (+ ), medium (+ + ), strong 
(+ + + ) or diffuse (+ + + + ) according to intensity and profile. Weak extravasation was defined as a faint cloud 
associated with one vessel leakage site; medium extravasation was defined as a bright cloud clearly associated with 
one vessel leakage site; strong extravasation was defined as a bright cloud associated with more than one vessel; 
diffuse extravasation was defined as an extensive leakage of the tracer in the interstitial perivascular space without 
any clear association with disrupted vessels.
Flow cytometry. The whole kidneys were reduced to single-cell suspensions by two digestions with col-
lagenase type 2 (Sigma) and collagenase/dispase (Roche). The preparations were filtered through a 40 μ m cell 
strainer (Becton Dickenson) and washed. The resulting single cells were collected, blocked in 5% v/v serum in 
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PBS, centrifuged and then stained with the following antibodies: anti-CD31 (BD) and anti-CD45 (BD). Cells 
were labeled using 7-amino-actinomyocin D before analysis to detect necrotic cells. All samples were collected 
by a CyAn™ ADP cytometer (DAKO). A biexponential analysis was performed using Summit V4.3 software and 
FlowJo X (Treestar) software.
Histological and immunofluorescence studies. Tissues were processed for cryosectioning or 
paraffin-embedding using standard methods. Kidney slices were stained with hematoxylin/eosin and PAS. Images 
were acquired using a bright field Aperto CS scanner and stored for subsequent analysis. Image Scope® software 
was used to measure glomerular size, cellularity and mesangial matrix expansion and deposition. A single-blind 
operator performed all analyses. Glomerular diameters were measured in all visible glomeruli in the histological 
section by taking the maximum diameter from the hilum to the end of the Bowman’s capsule. Glomerular cel-
lularity and mesangial matrix deposition were assessed through a specific program quantified by Image Scope 
algorithm (Positive pixel count version 8.100). Frozen slices were pre-blocked with serum and incubated with 
the following antibodies: rat anti-CD31 (eBioscience) followed by donkey anti–rat FITC–conjugated antibod-
ies (Jackson Immunology), rabbit anti-NG2 followed by donkey anti–rabbit Cy5–conjugated antibodies. Images 
were analyzed with a Leica confocal microscope (TCS-SP2) and by Image-J software (NIH, Bethesda, USA). 
Capillary density was quantified from at least five high-power fields (× 40) per slide, two slides per animal (3 
animals per group). Sections were randomly selected and analyzed under blinded conditions.
MicroRNA quantification. Kidney samples were homogenized with Trizol. Total RNA was purified and 
miRNA was extracted using a miRNA Isolation Kit (Qiagen). 10 ng of RNA were reverse transcribed using 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). For cDNA synthesis, the reaction mixture 
was incubated at 16 °C for 30 minutes and then at 42 °C for 30 minutes; the enzyme was then inactivated at 85 °C 
for 5 min. 1.5 μ L of the cDNA solution was then amplified using TaqMan Universal PCR Master Mix (Applied 
Biosystems), with miRNA-specific primer/probe (hsa-miR-22 000398, Thermo Fischer). The quantitative PCR 
was run on an ABI PRISM 7500 Real-time PCR system (Applied Biosystems) with an initial denaturation step 
at 95 °C for 10 minutes, followed by 40 cycles with a denaturation step at 95 °C for 15 seconds and an annealing/
elongation step at 60 °C for 60 seconds. Each sample was run in triplicate for analysis. The miRNA expression 
levels were normalized to U6 snRNA (001973, Thermo Fischer).
NGAL, TGFβ, BMP7 quantification. RNA was extracted using the Trizol protocol followed by DNase 
digestion to remove any contaminating genomic DNA. Total RNA concentration and purity were estimated 
using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher SCIENTIFIC). 1 μ g of RNA from each 
sample was reverse transcribed using the high capacity cDNA reverse transcription kit (Applied Biosystem). 
cDNA served as the template for subsequent PCR amplification with the following primers: mNGAL Fw 
5-CTCAGAACTTGATCCCTGCC-3 and mNGAL Rw 5-TCCTTGAGGCCCAGAGACTT-3; mTGFβ 
1 Fw: TGACGTCACTGGAGTTGTACGG and mTGFβ 1 Rw: GGTTCATGTCATGGATGGTGC; mBMP7 
Fw 5-TGAGCTTCGTCAACCTAGTG-3 and mBMP7 Rw 5-TCCTTATAGATCCTGAATTCGG-3; 18S Fw 
5-CCAGTAAGTGCGGGTCATAAGC-3 and Rw 5-AACGATCCAATCGGTAGTAGCG-3; mGAPDH Fw 
5-AGGTCGGAGTCAACGGATTT-3 and mGAPDH Rw 5-GTGATGGCATGGACTGTGGT-3 as the internal 
control. Quantitative PCR (GoTaq, qPCR master mix, Promega) was run on an ABI PRISM 7500 Real-time PCR 
system (Applied Biosystems) with an initial denaturation step at 95 °C for 10 minutes, followed by 40 cycles with 
a denaturation step at 95 °C for 15 seconds and an annealing/elongation step at 60 °C for 60 seconds. Each sample 
was run in triplicate for analysis.
Cell culture and treatment. Primary cultures of human umbilical vein endothelial cells (HUVECs) were 
obtained from ATCC and cultured as previously described27. For PDE5 hyperexpression, 105 TU/ml of pCCL.sin.
cPPT.hPGK.mPDE5 lentiviral vector (LV) was used to transduce HUVECs. To generate pCCL.sin.cPPT.hPGK.
mPDE5, PDE5A was amplified from whole murine embryonic RNA by RT-PCR using a reverse primer and 
cloned between AgeI (5′ ) and SalI (3′ ) restriction sites into pCCL.sin.cPPT.hPGK. VSV-pseudotyped LV pCCL.
sin.cPPT.hPGK.mPDE5 concentrated stocks were produced and titrated as described27. Transduced stable cells 
(PGK-PDE5) were used 10 days after infection. Cells were maintained for 24 hours in the presence of sildenafil 
(5 μ M) or vehicle and analyzed for miR-22 expression.
Statistical Analysis. All statistical analyses were carried out in accordance with a predetermined statistical 
analysis plan. The change from baseline was the post-baseline value minus the baseline value. The normality of 
distribution for all measurements at all time points was assessed by Shapiro-Wilk’s test (p > 0.05). The changes 
from baseline to week 4 were also analyzed with an ANOVA model that included the baseline as the covariate 
and treatment as the fixed effect. The ANOVA model used the last observation carried forward principle. Data 
are reported as mean with 95% Confidence Interval (95% CI) unless otherwise specified, whereas variables are 
reported as mean ± SD. A two-sided P-value of less than 0.05 was regarded as significant. Pearson’s correlation 
test was used to measure any linear association between variables. All analyses were performed using SPSS 18.0 
(SPSS, Inc).
Results
Effect of sildenafil on metabolism and renal function of diabetic mice. All mice receiving strep-
tozotocin (STZ and STZ + SILD groups) exhibited chronic hyperglycemia and glycosuria. The mean change in 
blood glucose levels from baseline in STZ and STZ + SILD mice was respectively 476.93 mg/dl (95% CI: 412.43 
to 541.42) and 448.65 mg/dl (95% CI: 382.92 to 514.37), (Fig. 1A). The mean change in urine glucose levels was 
2063.76 mg/dl (95% CI: 2005.07 to 2122.44) and 1992.45 mg/dl (95% CI: 1933.72 to 2051.18), (Fig. 1B). Blood 
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and urine glucose levels were similar in sildenafil- and vehicle-treated diabetic mice. No changes were found in 
the non-diabetic groups (CTRL and SILD).
Induction of diabetes with STZ produced a weight loss that was attenuated by sildenafil. The mean change from 
baseline was − 10.05 g (95% CI: − 16.51 to − 3.60) in STZ and − 3.80 g (95% CI: − 9.87 to 2.26) in STZ + SILD. 
Least square (LS) mean differences among groups were as follows: STZ vs. CTRL − 13.91 (95% CI: − 25.54 to 
− 2.29), P = 0.024; STZ vs. SILD − 10.61 (95% CI: − 19.97 to − 1.26), P = 0.030. Interestingly, sildenafil reduced 
weight loss to a level not statistically different from the non-diabetic groups: STZ + SILD vs. CTRL − 7.66 g (95% 
CI: − 18.40 to 3.07), P = 0.141, STZ + SILD vs. SILD − 4.36 g (95% CI: − 13.55 to 4.82), P = 0.311, (Fig. 1C).
Hypertriglyceridemia in diabetic mice improved after sildenafil, with a LS mean difference between 
STZ + SILD and STZ of − 116.16 mg/dl (95% CI: − 136.05 to − 96.97), P < 0.001 (Fig. 1D). MAP was higher in 
diabetic mice and lower in sildenafil-treated animals. The mean change from baseline was 25.75 mmHg (95% 
CI: 21.53 to 29.96) and − 3.68 mmHg (95% CI: − 8.89 to 1.52) respectively in STZ and STZ + SILD; LS mean 
difference − 29.42 mmHg (95% CI: − 36.01 to − 22.83, P < 0.001). In contrast, there were no differences in blood 
pressure between STZ + SILD and non-diabetic mice (Fig. 1E).
There was no difference in HR between the four groups (Fig. 1F). In diabetic mice, elevated serum creati-
nine was lowered by sildenafil treatment: mean change from baseline 0.23 mg/dl (95% CI: 0.17 to 0.28) in STZ 
and 0.07 mg/dl (95% CI: 0.02 to 0.13) in STZ + SILD; LS mean difference − 0.15 mg/dl (95% CI: 0.23 to − 0.08), 
P < 0.01 (Fig. 2A).
As expected, the urinary albumin/creatinine ratio (ACR) increased in diabetic mice during the observation 
period: mean change from baseline 1135.58 μ g/mg (95% CI: 1012.00 to 1259.15) in STZ and 331.65 μ g/mg (95% 
CI: 204.80 to 458.49) in STZ + SILD. Sildenafil treatment significantly attenuated ACR: LS mean difference 
− 803.93 μ g/mg (95% CI: − 985.84 to − 622.01), P < 0.001 (Fig. 2B,C). Even when corrected for MAP, the LS mean 
difference was − 893.48 μ g/mg (95% CI: − 1343.12 to − 443.84), P = 0.002.
GFR was estimated using a single bolus injection of FITC-inulin. The mean change from baseline was unre-
markable in the CTRL group, but significantly different in STZ: − 18.07 ml/min (95% CI: − 20.84 to − 15.30), and 
in STZ + SILD: 21.28 ml/min (95% CI: 18.63 to 23.93). Sildenafil protected against the decline in renal function 
induced by diabetes: LS mean difference was 39.35 mL/min (95% CI: 35.43 to 43.28), P < 0.001, (Fig. 2D). This 
effect was retained even when adjusted for MAP: LS mean difference was 39.22 mL/min (95% CI: 19.18 to 59.35), 
P = 0.002.
Soluble urokinase-type plasminogen activator receptor (suPAR), a candidate biomarker for incipient chronic 
kidney disease, was markedly elevated in STZ mice: mean change from baseline 1516.58 pg/ml (95% CI: 1315.09 
to 1718.07) and only modestly increased in sildenafil-treated diabetic mice: mean change from baseline 227.64 pg/
ml (95% CI: 24.40 to 430.88). The LS mean difference between treatments was highly significant, at − 1288.94 pg/
Figure 1. LS mean change from the baseline in: (A) plasma glucose, (B) urine glucose, (C) weight,  
(D) triglycerides, (E) MAP, (F) HR in CTRL, SILD, STZ and STZ + SILD mice. Error bars represent upper and 
lower 95% CI; *P < 0.05, ***P < 0.001 vs. CTRL; #P < 0.05, ###P < 0.001 vs. SILD; •••P < 0.001 vs. STZ.
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ml (95% CI: − 1575.34 to − 1002.54), P < 0.001 (Fig. 2E). Neutrophil gelatinase-associated lipocalin (NGAL), 
strongly expressed in the kidney following ischemic or nephrotoxic injury, also proved to be modulated by silde-
nafil in DN: STZ + SILD vs. STZ, P < 0.05 (Fig. 2F). All this converging evidence supports the assertion that 
sildenafil protects the kidneys against the progression of diabetic damage.
Effects of sildenafil on kidney microcirculation assessed by RDU. Non-invasive measurement of 
vascular resistance can be estimated by RRI using RDU (Fig. 3A). RRI of the interlobular arteries was increased 
in STZ mice compared to CTRL mice and STZ + SILD mice. The mean change in RRI from the baseline was 0.10 
(95% CI: 0.06 to 0.13) and − 0.06 (95% CI: − 0.10 to 0.02) respectively in STZ and STZ + SILD mice, and the 
treatment-related LS mean change was − 0.16 (95% CI: − 0.22 to − 0.09), P < 0.001. No differences were observed 
between STZ + SILD and CTRL: LS mean change − 0.05 (95% CI: − 0.11 to 0.01), P = 0.120, suggesting that 
the effect of sildenafil completely reversed the change in RRI. However, a statistically significant difference was 
observed between STZ + SILD and SILD: LS mean change 0.07 (95% CI: − 0.02 to 0.12), P = 0.013, (Fig. 3B), sug-
gesting that there is also a vasoactive effect independent of the reversal of diabetic damage. The mean change from 
the baseline in RRI was inversely correlated with the mean change from baseline in GFR (r = − 0.766, P < 0.001), 
(Fig. 3C), even when adjusted for MAP (r = − 0.435, P = 0.014), suggesting that renal hemodynamics play a lead-
ing role in determining renal function response.
In vivo evaluation by RDU also showed a reduction in renal volume in STZ treated animals, that was reversed 
in STZ + SILD: the LS mean difference was 0.83 mL (95% CI: 0.19 to 1.47), P = 0.016. There was no difference in 
renal volume between diabetic mice treated with sildenafil and non-diabetic CTRL or SILD animals (Fig. 3D). 
The RDU measurement accuracy was confirmed by analysis of renal weight after harvesting. STZ mice showed 
a significant reduction in the kidney weight/tibial length ratio, whereas STZ + SILD had a ratio comparable 
with non-diabetic groups, (STZ + SILD: 17.69 ± 2.27 vs. CTRL: 17.94 ± 1.72 g/mm, P = 0.874, and vs. SILD: 
16.25 ± 1.09 g/mm, P = 0.323, and higher than STZ: 13.85 ± 1.23 g/mm, P = 0.034), (Fig. 3E).
Histological changes induced by diabetes correlate with RRI and are prevented by sildena-
fil. Diabetes induction reduced glomerular diameter, produced focal and segmental hyperplasia with dif-
fuse mesangial proliferation and increased mesangial matrix deposition (Fig. 4A–D). At the end of treatment, 
an inverse correlation was found between RRI and glomerular diameters: r = − 0.712, P = 0.002 (Fig. 4C). In 
STZ-only treated mice there were areas of acute tubular degeneration, eosinophilia and proximal tubule basal 
Figure 2. LS mean change from the baseline in: (A) creatinine, (B) ACR in CTRL, SILD, STZ and STZ + SILD 
mice. Error bars represent upper and lower 95% CI; **P < 0.01, ***P < 0.001 vs. CTRL; ##P < 0.01, ###P < 0.001 
vs. SILD; ••P < 0.01, •••P < 0.001 vs. STZ. (C) quantification (mean ± SE) of ACR over time course, in STZ and 
STZ + SILD groups, ••P < 0.05, ••P < 0.01 between groups. LS mean change from the baseline of (D) GFR, and 
(E) suPAR, in CTRL, SILD, STZ and STZ + SILD mice. Error bars represent upper and lower 95% CI; *P < 0.05, 
***P < 0.001 vs. CTRL; ###P < 0.001 vs. SILD; •••P < 0.001 vs. STZ. (F) relative expression of NGAL, mean ± SD, 
in CTRL, SILD, STZ and STZ + SILD mice. *P < 0.05 vs. CTRL; #P < 0.05 vs. SILD; •P < 0.05 vs. STZ.
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membrane thickening. Sildenafil treatment did not reduce mesangial proliferation induced by STZ, but reduced 
mesangial matrix deposition (Fig. 4A,D) (P < 0.05). Focal and segmental capillary ectasia was observed in SILD 
and STZ + SILD groups (Fig. 4A,D). A significant correlation between mean change from baseline of RRI and 
mesangial matrix deposition score (r = 0.627, P = 0.009), was found among groups, suggesting that parenchy-
mal stiffness associated with increased mesangial deposition directly contributes to increased resistance of the 
interlobular arteries. No change was found between RRI and mesangial proliferation score (r = 0.116, P = 0.669). 
There was an inverse correlation between RRI and glomerular vessel diameter (r = − 0.703, P = 0.002). Overall, 
these data indicate that hemodynamic changes induced by diabetes, and reversed by sildenafil, mirror discrete 
changes in the parenchymal and glomerular structure of the kidney.
Figure 3. (A) representation of RDU image, RRI measurement (on the right) and volume measurement (on the 
left); (B) LS mean change from baseline of RRI in CTRL, SILD, STZ and STZ + SILD mice. Error bars represent 
upper and lower 95% CI; ***P < 0.001 vs. CTRL; #P < 0.05, ###P < 0.001 vs. SILD; •••P < 0.001 vs. STZ.  
(C) correlation between mean change from the baseline in GFR (Y axis) and in RRI (X axis), r = − 0.766, 
P < 0.001; (D) LS mean change from baseline of renal volume in CTRL, SILD, STZ and STZ + SILD mice. Error 
bars represent upper and lower 95% CI; •P < 0.05 vs. STZ. (E) kidney weight/tibial length ratio, mean ± SD, in 
CTRL, SILD, STZ and STZ + SILD mice. *P < 0.05, vs. CTRL; #P < 0.05 vs. SILD; •P < 0.05 vs. STZ.
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Sildenafil improves microcirculation in the diabetic kidney. Microvascular impairment has an 
important role in the progression of chronic kidney diseases. Disruption of the endothelium (due to injury or 
non-renewal) contributes to increased vascular permeability. Vascular leakage was quantified by Evan’s blue 
dye in kidney tissue. In the kidney of STZ mice, the amount of Evan’s blue dye/mg tissue was higher than in 
non-diabetic mice (STZ vs. CTRL P < 0.01 and vs. SILD P < 0.01) and was partially reversed by sildenafil treat-
ment (STZ vs. STZ + SILD P < 0.01), (Fig. 4E), suggesting that sildenafil protected against the increased vascular 
leakage associated with diabetes.
Vascular permeability was also assessed by FITC-dextran. In healthy animals, plasma injection with 
FITC-dextran labeled the inner lumen of glomerular capillaries. In diabetic animals, a substantial increase in 
FITC-dextran glomerular extravasation was observed compared to non-diabetic (P < 0.05), which was partially 
reversed by sildenafil (P < 0.05), (Fig. 4F).
Since there is a loss of EC in DN28, we evaluated the expression of the EC marker CD31. Capillary density as 
quantified by CD31+ area, was reduced in STZ mice compared to non-diabetic mice (STZ vs. CTRL, P = 0.019; STZ 
vs. SILD, P = 0.007), but partially restored by sildenafil treatment (STZ vs. STZ + SILD, P = 0.024). CD31+ area was 
similar in all non-diabetic and sildenafil treated mice, (Fig. 5A,B). Given the reduction in EC, which might be due to 
impaired perivascular cell function, we investigated vascular architecture by double staining for CD31 and a pericyte 
marker, NG2. Pericyte coverage of the endothelium, quantified as percentage of NG2+/CD31+ area ratio, revealed 
a disassociation of pericytes in the STZ group that was preserved in STZ + SILD mice (respectively 10 ± 7% vs. 
60 ± 8%, P < 0.01) to a level comparable to CTRL mice (Fig. 5C,D). To better characterize the pattern of CD31+ loss, 
we analyzed CD31+ cells in renal tissue by flow cytometry at different time points (Fig. 5E). This revealed a reduction 
of CD31+ EC in STZ mice, which was already detectable from the second week after diabetes induction (week 2: STZ 
vs. CTRL, P = 0.002; STZ vs. SILD, P = 0.004; STZ vs. STZ + SILD, P = 0.005) and increased thereafter, suggestive of 
EC death. Sildenafil prevents EC loss along the entire observation time (week 4: STZ vs. CTRL, P = 0.005; STZ vs. 
Figure 4. (A) representative photomicrographs of PAS-stained kidneys of STZ and STZ + SILD mice,bar 
represent 60 μ m; (B) glomerular diameters, mean ± SD, in STZ and STZ + SILD mice. ••P < 0.01;  
(C) correlation between glomerular diameter (Y axis) and RRI (X axis) at the end of observation period, r =  
− 0.712, P = 0.002; (D) relative quantification, mean ± SD, of mesangial matrix, mesangial proliferation, vessel 
dilatation in STZ and STZ + SILD mice, •P < 0.05; (E) quantification, mean ± SD, of Evan’s Blue dye/mg tissue 
in CTRL, SILD, STZ and STZ + SILD mice, **P < 0.01 vs. CTRL; ##P < 0.01 vs. SILD; ••P < 0.01 vs. STZ. (F) 
rapresentation of vascular permeability express as degree of extravasation (+ ) by FITC dextran in CTRL, SILD, 
STZ and STZ + SILD mice, bar represent 30 μ m.
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SILD, P = 0.008; STZ vs. STZ + SILD, P = 0.007), (Fig. 5F). Collectively, these data indicate that sildenafil protected 
the renal microcirculation by favoring vascular integrity in diabetic mice.
Sildenafil upregulates BMP7 and downregulates miR-22 in diabetic kidney. Bone morphogenetic 
protein-7 (BMP7) is known to be a critical molecule in inducing angiogenesis, protecting EC from apoptosis and 
antagonizing TGF-β -dependent fibrosis29. We observed a BMP7 downregulation in diabetic kidney (P < 0.05) 
and, conversely, an increased expression of BMP7 after sildenafil treatment (P < 0.05), (Fig. 6A). This was also 
associated with downregulation of BMP7-antagonist TGF-β (P < 0.05), (Fig. 6B). It was previously demonstrated 
that BMP7 is regulated by miR-2230. In light of the observed downregulation of miR-22 in adipose tissue after 
sildenafil treatment31, we decided to verify whether miR-22 underwent a similar pattern of downregulation in 
kidney. To this end, we examined miR-22 expression by qPCR, finding that it was downregulated by sildenafil ~3 
fold (P < 0.001), (Fig. 6C). This supports the nephroprotective role of PDE5i through the miR-22/BMP7 axis. We 
also extended our in vivo observations, investigating whether the PDE5 pathway was directly involved in miR-
22 expression in endothelial cells (HUVEC). We engineered HUVEC to trigger PDE5 hyper-expression and we 
found that miR-22 was highly upregulated (P < 0.01), with downregulation after sildenafil treatment occurring 
in both transduced (P < 0.001) and non-transduced cells (P < 0.01), (Fig. 6D). This indicates both a strong asso-
ciation between PDE5 and miR-22 expression and the ability of sildenafil to induce a marked reduction in this 
damage marker.
Discussion
Experimental and clinical data support the hypothesis that PDE5is could act as nephroprotective agents and 
current interest has shifted from their cardioprotective32–34 to their nephroprotective13–18,35,36 properties. In a 
recent clinical trial, a novel long-acting PDE5i, PF-00489791, was effective in reducing albuminuria in diabetic 
patients stably treated with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers 
(ARBs). This reduction occurred without any changes in GFR and independently of changes in blood pressure37. 
Figure 5. (A) Immunofluorescence of CD31+ areas in CTRL, SILD, STZ and STZ + SILD mice, bar represent 
60 μ m; (B) Quantification, mean ± SD, of capillary density, expressed as percentage of CD31+ area in CTRL, 
SILD, STZ and STZ + SILD mice. *P < 0.05 vs. CTRL; ##P < 0.01 vs. SILD; •P < 0.05 vs. STZ;  
(C) Immunofluorescence of CD31+ (green) and NG2+ (red) areas in CTRL, SILD, STZ and STZ + SILD 
mice, bar represent 60 μ m; (D) Quantification, mean ± SD, of pericytes coverage, expressed as percentage of 
ratio NG2+/CD31+ area in CTRL, SILD, STZ and STZ + SILD mice. **P < 0.01 vs. CTRL; ##P < 0.01 vs. SILD; 
••P < 0.01 vs. STZ; (E) Representative gating of CD31+CD45− cells. (F) Percentage of CD31+CD45− EC in 
kidney, before and after STZ induction in CTRL, SILD, STZ and STZ + SILD mice. **P < 0.01 between STZ and 
CTRL, SILD and STZ + SILD groups.
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This prompted us to investigate the mechanisms involved in sildenafil’s protection in DN. We used a high-dose 
STZ model after pretreatment with a sodium/glucose cotransporter inhibitor, phlorizin, which reduces the risk 
of any acute nephrotoxic effects of STZ, while maintaining the known β -cell toxicity26. We found that sildenafil 
prevented renal function from worsening, as shown by GFR and ACR, improved microcirculation, by means of 
in vivo assessment of RRI, and slowed the progression of DN, specifically targeting mesangial matrix expansion, 
capillary and glomerular diameter. We then provided molecular insights into involvement of the miR-22 and its 
direct target BMP7 in modulating angiogenesis and vascular stability in the diabetic kidney.
Previous studies clearly demonstrated that a rise in cGMP levels and enhanced eNOS expression following 
PDE5 inhibition is essential for the maintenance of renal perfusion and glomerular filtration. However, the direct 
effects of NO in glomerular hemodynamics include preglomerular vasodilatation38, therefore PDE5 inhibition 
would be expected to aggravate, rather than improve, the glomerular hypertension and hyper-filtration triggering 
progressive glomerulosclerosis in DN. In addition, blood pressure lowering agents such as ACEi or ARBs have 
been associated with short-term lowering of GFR39, in contrast with other studies37, and in this study we demon-
strate that GFR and ACR are modulated by sildenafil independently of MAP changes. This seems to suggest that 
the nephroprotective effects of PDE5i are not secondary to a reduction in systemic hypertension, but rather are 
exerted through a modulation of intraglomerular hemodynamics.
In line with its protective effects we also found a reduced expression of nephropathy biomarkers such as 
NGAL and suPAR in sildenafil treated mice. A rise in suPAR increases glomerular permeability, leading to a 
cascade of events that result in focal segmental glomerulosclerosis; suPAR is thus emerging as a new biomarker 
for chronic kidney disease40.
An advantage of this study is its in vivo assessment of interlobular renal arteries by RDU, which is gaining 
momentum in the early identification of morphologic and hemodynamic renal changes in diabetic patients41. 
Increased RRI is correlated with renal dysfunction42, T2DM and chronic nephropathies43,44, and, in the absence 
Figure 6. (A) Relative quantification, mean ± SD, of BMP7/18S by qPCR in kidney of CTRL, SILD, STZ 
and STZ + SILD mice. *P < 0.05 vs. CTRL, #P < 0.05 vs. SILD, •P < 0.05 vs. STZ; (B) Relative quantification, 
mean ± SD, of TGFβ /18S by qPCR in kidney of CTRL, SILD, STZ and STZ + SILD mice. *P < 0.05 vs. CTRL, 
#P < 0.05 vs. SILD, •P < 0.05 vs. STZ; (C) Relative quantification, mean ± SD, of miR-22/U6B by qPCR in 
kidney of CTRL, SILD, STZ and STZ + SILD mice. *P < 0.05 and ***P < 0.001 vs. CTRL, ###P < 0.001 vs. SILD, 
•••P < 0.001 vs. STZ; (D) Relative quantification, mean ± SD, of miR-22/U6B by qPCR in HUVEC untreated, 
treated with sildenafil, PKG-PDE5-transduced, PGK-PDE5-transduced and treated with sildenafil. **P < 0.01 
vs. CTRL, ###P < 0.001 vs. SILD, •••P < 0.001 vs. PGK-PDE5.
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of macrovascular disease, reflects the integrity of the renal microcirculation45. PDE5is have been shown to offer 
vascular protection in hypertension46, however to the best of our knowledge no studies have used RDU to inves-
tigate in vivo the effect of PDE5is in a mouse model of DN. As seen in diabetic patients24, RRI inversely corre-
lated with GFR. Increased RRI can reflect changes in intraglomerular hemodynamics, but also a deterioration 
in tissue architecture due to a reduction of intravessel area and tissue stiffness and consequent increase vascular 
resistance42. We clearly observed an increase of RRI in diabetic mice; this was correlated with histopathological 
changes and was reduced by sildenafil. These observations point to the direct modulation of renal microcircula-
tion by PDE5i.
Sildenafil treatment determined an improvement in the renal vascular rarefaction induced by diabetes and 
also limited EC-pericytes detachment. It has been postulated that PDE5i ameliorated endothelial function19,20. 
It was recently demonstrated that sildenafil recovered the endothelial surface and eliminated oxidative stress in 
an experimental model of hypertension, reducing blood pressure and improving the endothelium-dependent 
relaxation35,47.
BMP7 plays a pivotal role in kidney homeostasis by antagonizing the TGFβ -induced profibrotic signals and 
counteracting the TGFβ -induced pericytes-to-myofibroblast transition29. Its anti-fibrotic action could restore 
vascular stability and limit capillary rarefaction. The beneficial effects of BMP7 signaling in diabetic nephropathy 
were confirmed in pharmacological transgenic mice models overexpressing BMP7 in podocytes and proximal 
tubules48. Recombinant BMP7 therapy has been shown to inhibit fibrosis progression in a variety of mouse mod-
els of renal fibrosis, including the STZ49 diabetic mice. In this study, we demonstrate that sildenafil increases 
BMP7 expression in diabetes and that such effect occurs alongside the downregulation of miR-22, a known reg-
ulator of BMP7. The enhanced BMP7 expression seen with sildenafil administration could explain the vessel 
structure preservation and limited mesangial expansion occurring in diabetic mice treated with PDE5i. MiR-22 
is known to directly target BMP7, and deletion of miR-22 significantly attenuated renal fibrosis30. MiR-22 is also 
involved in blood pressure regulation. In vivo administration of antagomir of miR-22 to spontaneously hyperten-
sive rat reduced blood pressure and revealed a new avenue for treatment of hypertension50. We recently demon-
strated that sildenafil determined a downregulation of circulating miR-22 in diabetic patients and in adipose 
tissue of db/db mice31. In the present study, we confirmed the downregulation of miR-22 by sildenafil in diabetic 
kidney and upregulation of its target BMP7, associated with tissue protection. Importantly, we provide a confir-
mation of involvement of PDE5 signaling on miR-22 expression.
However, this study has some limitations. First, we cannot demonstrate how sildenafil modulates the elements 
regulating miR-22 gene expression. Second, the relatively short observation period could not discern whether 
sildenafil acts on DN development or progression; long-term studies are warranted to address this issue. Finally, 
further studies on DN under controlled genetic and environmental conditions mouse models and/or in combina-
tion with hypoglycemic therapies could help to better investigate the therapeutic benefit of PDE5is.
This study extends our previous findings on the effect of PDE5is on diabetic vascular complication, supporting 
their therapeutic role in slowing the natural progression of kidney damage during DN.
Our results demonstrate that metabolic, hemodynamic and epigenetic factors combine to preserve vessel 
structure and function in DN and uncover the novel role of PDE5i/miR-22 regulatory relationship, which helps 
to preserve BMP7 homeostasis in the kidney. Translational confirmatory findings will reveal novel treatment 
strategies for diabetic nephrovascular disease that could be immediately transferred to clinical practice.
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